Transport of glial cell line-derived neurotrophic factor into liposomes across the blood-brain barrier: In vitro and in vivo studies

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 3612-3623

  Wu, Shaoling ^a   Li, Guoqi ^a   Li, Xiao ^a   Lin, Caina ^a   Yu, Ding ^a   Luan, Shuo ^a   Ma, Chao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Glial cell line derived neurotrophic factor; Target sterically stabilized liposomes

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LIATERMIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CIRCULATION TIME; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DELIVERY SYSTEM; ELECTRIC RESISTANCE; ENZYME ACTIVITY; ENZYME DEGRADATION; EVAPORATION; IMMUNOCYTOCHEMISTRY; LIPOPHILICITY; MALE; NANOENCAPSULATION; NONHUMAN; PHASE CONTRAST MICROSCOPY; RAT; ANIMAL; ASTROCYTE; BIOLOGICAL MODEL; BRAIN; CAPILLARY; CAPILLARY PERMEABILITY; CELL CULTURE; CYTOLOGY; ENDOTHELIUM CELL; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; TIME; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ANIMALS; ASTROCYTES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CAPILLARY PERMEABILITY; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LIPOSOMES; MODELS, BIOLOGICAL; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84895486074     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15033612     Document Type: Article

References (37)

1. Allen, S.J.; Watson, J.J.; Shoemark, D.K.; Barua, N.U.; Patel, N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 2013, 138, 155-175.
2. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260, 1130-1132.
3. Nosrat, C.A.; Tomac, A.; Lindqvist, E.; Lindskog, S.; Humpel, C.; Stromberg, I.; Ebendal, T.; Hoffer, B.J.; Olson, L. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res. 1996, 286, 191-207.
4. Barroso-Chinea, P.; Cruz-Muros, I.; Aymerich, M.S.; Rodriguez-Diaz, M.; Afonso-Oramas, D.; Lanciego, J.L.; González-Hernández, T. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur. J. Neurosci. 2005, 21, 1815-1827.
5. Pascual, A.; Hidalgo-Figueroa, M.; Piruat, J.I.; Pintado, C.O.; Gomez-Diaz, R.; Lopez-Barneo, J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11, 755-761.
6. Beck, K.D.; Valverde, J.; Alexi, T.; Poulsen, K.; Moffat, B.; Vandlen, R.A.; Rosenthal, A.; Hefti, F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995, 373, 339-341.
7. Tomac, A.; Lindqvist, E.; Lin, L.F.; Ogren, S.O.; Young, D.; Hoffer, B.J.; Olson, L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373, 335-339.
8. Moore, M.W.; Klein, R.D.; Farinas, I.; Sauer, H.; Armanini, M.; Phillips, H.; Reichardt, L.F.; Ryan, A.M.; Carver-Moore, K.; Rosenthal, A. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382, 76-79.
9. Ledda, F.; Paratcha, G.; Sandoval-Guzman, T.; Ibanez, C.F. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat. Neurosci. 2007, 10, 293-300.
10. Hirsch, E.C.; Hunot, S.; Faucheux, B. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. 1999, 14, 383-385.
11. Sinclair, S.R.; Svendsen, C.N.; Torres, E.M.; Martin, D.; Fawcett, J.W.; Dunnett, S.B. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 1996, 7, 2547-2552.
12. Björklund, A.; Kirik, D.; Rosenblad, C.; Georgievska, B.; Lundberg, C.; Mandel, R.J. Towards a neuroprotective gene therapy for Parkinson disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000, 886, 82-98.
13. Gash, D.M.; Zhang, Z.; Ovadia, A.; Cass, W.A.; Yi, A.; Simmerman, L.; Russell, D.; Martin, D.; Lapchak, P.A.; Collins, F.; et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380, 252-255.
14. Yang, W.H.; Yang, C.; Xue, Y.Q.; Lu, T.; Reiser, J.; Zhao, L.R.; Duan, W.M. Regulated expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its neuroprotection on dopaminergic cells in vitro. PLoS One 2013, 22, e64389.
15. Garbayo, E.; Montero-Menei, C.N.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's Disease. J. Control. Release 2009, 135, 119-126.
16. Fletcher, A.M.; Kowalczyk, T.H.; Padegimas, L.; Cooper, M.J.; Yurek, D.M. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neu-roscience 2011, 194, 220-226.
17. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145-160.
18. Ramos-Cabrer, P.; Campos, F. Liposomes and nanotechnology in drug development: Focus on neurological targets. Int. J. Nanomed. 2013, 8, 951-960.
19. Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M.P.; Fenart, L. Modelling of the blood-brain barrier indrug discovery and development. Nat. Rev. Drug Discov. 2007, 6, 650-661.
20. Liu, W.Y.; Wang, Z.B.; Zhang, L.C.; Wei, X.; Li, L. Tight junction in blood-brain barrier: An overview of structure, regulation, and regulator substances. CNS Neurosci. Ther. 2012, 18, 609-615.
21. Pardridge, W.M. BBB-Genomics: Creating new openings for brain-drug targeting. Drug Discov. Today 2001, 6, 381-383.
22. Markoutsa, E.; Pampalakis, G.; Niarakis, A.; Romero, I.A.; Weksler, B.; Couraud, P.O.; Antimisiaris, S.G. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur. J. Pharm. Biopharm. 2011, 77, 265-274.
23. Zhang, Y.; Schlachetzki, F.; Zhang, Y.F.; Boado, R.J.; Pardridge, W.M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 2004, 15, 339-350.
24. Chen, H.; Tang, L.; Qin, Y.; Yin, Y.; Tang, J.; Tang, W.; Sun, X.; Zhang, Z.; Liu, J.; He, Q. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 2010, 40, 94-102.
25. Qin, Y.; Fan, W.; Chen, H.; Yao, N.; Tang, W.; Tang, J.; Yuan, W.; Kuai, R.; Zhang, Z.; Wu, Y.; et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug Target. 2010, 18, 536-549.
26. Demeuse, P.; Kerkhofs, A.; Struys-Ponsar, C.; Knoops, B.; Remacle, C.; van den Bosch de Aguilar, P. Compartmentalized coculture of rat brain endothelial cells and astrocytes: A syngenic model to study the blood-brain barrier. J. Neurosci. Methods 2002, 121, 21-31.
27. Xie, Y.; Ye, L.; Zhang, X.; Cui, W.; Lou, J.; Nagai, T.; Hou, X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J. Control. Release 2005, 105, 106-119.
28. Senior, J.; Delgado, C.; Fisher, D.; Tilcock, C.; Gregoriadis, G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with PEGcoated vesicles. Biochim. Biophys. Acta 1991, 1062, 77-82.
29. Klibanov, A.L.; Maruyama, K.; Torchilin, V.P.; Huang, L. Amphipatic PEG effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268, 235-237.
30. Ying, X.; Wen, H.; Lu, W.L.; Du, J.; Guo, J.; Tian, W.; Men, Y.; Zhang, Y.; Li, R.J.; Yang, T.Y.; et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Release 2010, 141, 183-192.
31. Doctrow, S.R.; Abelleira, S.M.; Curry, L.A.; Heller-Harrison, R.; Kozarich, J.W.; Malfroy, B.; McCarroll, L.A.; Morgan, K.G.; Morrow, A.R.; Musso, G.F.; et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascullar endothelial cell. J. Pharmacol. Exp. Ther. 1994, 271, 229-237.
32. Bartus, R.T.; Elliott, P.J.; Dean, R.L.; Hayward, N.J.; Nagle, T.L.; Huff, M.R.; Snodgrass, P.A.; Blunt, D.G. Controlled modulation of BBB permeability using the bradykinin agonist RMP-7. Exp. Neurol. 1996, 142, 14-28.
33. Szoka, F., Jr.; Papahadjopoulos, D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. USA 1978, 75, 4194-4198.
34. Zhang, X.; Xie, J.; Li, S.; Wang, X.; Hou, X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target. 2003, 11, 117-122.
35. Lu, W.; Zhang, Y.; Tan, Y.Z.; Hu, K.L.; Jiang, X.G.; Fu, S.K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control. Release 2005b, 107, 428-448.
36. Lu, W.; Tan, Y.Z.; Hu, K.L.; Jiang, X.G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharm. 2005a, 295, 247-260.
37. Kurakhmaeva, K.B.; Djindjikhashvili, I.A.; Petrov, V.E.; Balabanyan, V.U.; Voronina, T.A.; Trofimov, S.S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R.N. Brain targeting of nerve growth factor using poly (butyl cyanoacrylate) nanoparticles. J. Drug Target. 2009, 17, 564-574.